The 6th International
Conference on Lung cancer and COPD is the world’s largest educational
and scientific conference, dedicated to lung
cancer and pulmonary diseases hosted on November 20-21 2019 Berlin, Germany. The congress
summarizes the recent developments and advancements in lung
cancer, COPD and pulmonary diseases research. The attendees of the conference include Medical Oncologists, Pulmonologists, Epidemiologists, Surgeons, Pathologists, Research Scientists, Respiratory Physicians, Health Care Professionals and representatives from
the academic and industrial experts.
Why to attend Lung Cancer and COPD Congress 2019?
Lung Cancer and COPD Congress 2019 provides a golden opportunity to meet the leading national and international speakers who will discuss the latest advancements in Lung cancer treatment, COPD, Pulmonary Diseases worldwide. COPD Conference 2019 unites individuals or eminent personalities from all over the world, who share a common discipline in lung diseases research. This conference is a collaborative event for the researchers from both business and academia background and offers current and recent information on the management of lung cancer, as well as the possible therapies and strategies to shape the future of lung cancer and COPD research. We encourage physicians, nurses, researchers and scientists as well as patients in the lung cancer field and those interested in attending to this Conference. It is only through an exchange of the widest variety of research we can offer the best program and benefits to our members and patients.
Abstract Submission & Important Dates
Abstract Submission Guidelines:
The length of the abstract must not exceed 300 words.
The title should be in sentence case.
Should write name of the author and co-authors (if any).
You must provide your full name, affiliation (degree, institution/company/University name, address, contact number and email address).
Short biography of the author (limited to 100 words).
They must be submitted before the deadlines.
All the abstracts will be reviewed by the committee and you will get an email within 24-48 hours after submission of your abstract.
All the accepted abstracts will be published in the conference proceeding books.
your Abstract: http://copd.alliedacademies.com/abstract-submission
Register now: http://copd.alliedacademies.com/registration
Session 1: Lung cancer
Cancerous tumour is a group of cancer cells that can grow into and destroy nearby tissue and can spread to other parts of the body. When cancer starts in lung cells, it is called as primary lung cancer. Cells in the lungs sometimes change and no longer grow or behave normally. These changes may lead to non-cancerous tumours such as hamartoma and papilloma.
Session 2: Stages & Severity of Lung Diseases
There are two stages in small cell lung cancer. They are limited stage and extensive stage. Whereas non-small cell lung cancer is divided into four different stages depending upon the tumour size and location, number of nearby lymph nodes that have involved and how far the cancer has spread.
Chronic obstructive pulmonary disease is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. It mainly affects middle-aged or older adults who smoke.it is not contagious. The breathing problems gradually worsen over time and can limit normal activities, particularly if smoking exposure continues increasing breathlessness.
Session 6: Surgical & Radiation Oncology
Surgical oncology is the branch of surgery applied to cancer; it focuses on the surgical management of tumours, especially cancerous tumours. As one of several modalities in the management of cancer, the specialty of surgical oncology, before modern medicine the only cancer treatment with a chance of success, has evolved in steps similar to medical oncology (pharmacotherapy for cancer), which grew out of haematology, and radiation oncology, which grew out of radiology. The proliferation of cancer centres will continue to popularize the field, as will developments in minimally invasive techniques, palliative surgery, and neo-adjuvant treatments. Radiation oncology is one of the three primary specialties, the other two being surgical and medical oncology, involved in the treatment of cancer. A Radiation Oncologist is a specialist physician who uses ionizing radiation (such as megavoltage X-rays or radionuclides) in the treatment of cancer. Brachytherapy is an advanced cancer treatment. Radioactive seeds or sources are placed in or near a tumour itself, giving a high radiation dose to a tumour while reducing the radiation exposure in the surrounding healthy tissues. External beam therapy (EBT), also called external radiation therapy, is a method for delivering a beam or several beams of high-energy x-rays to a patient's tumour. Intraoperative radiation therapy or IORT is the application of therapeutic levels of radiation to the tumour bed while the area is exposed during surgery.
Session 7: Comorbidities of Pulmonary Diseases
COPD, like other chronic disorders, has been associated with comorbidities that increase in number and severity with age. Comorbidities increase the risk for exacerbations and increase the risk of mortality. Over 80% of patients with COPD were estimated to have at least one comorbid chronic condition. Comorbidities like diabetes mellitus, cardiac disease, osteoporosis, hypertension, cachexia, sleep disturbance, and psychological disorders are commonly reported in patients with chronic obstructive pulmonary disease (COPD). Tobacco smoking is main risk factor for many of these comorbidities as well as for COPD.
Session 8: Lung Diseases, Cancer & its Epidemiology
Chronic obstructive pulmonary disease is responsible for early mortality, high death rates and significant cost to health systems. The projection for 2020 indicates that COPD will be the third leading cause of death in the world. Active smoking remains the main risk factor, but other factors such as occupational factors, infections and the role of air pollution also play a major role. Prevalence of COPD varies according to the country, age and sex. The major challenge in the coming years will be to prevent onset of smoking along with early detection of the disease in the population. An estimated 328 million people have COPD worldwide and in 15 years, COPD is expected to become the leading cause of death worldwide.
Session 10: Clinical Trials on COPD
Session 11: Cancer Biology & Genetics
Cancer is caused when cells within the body accumulate genetic mutations and start to grow in an uncontrolled manner. Understanding how cancer develops and progresses, including how gene mutations drive the growth and spread of cancer cells, and how tumors interact with their surrounding environment, is vital for the discovery of new targeted cancer treatments.
Oncogenes & Proto-oncogenes
Tumor Suppressor Genes
Importance & Scope of Lung Cancer And COPD Conference 2019
The global lung cancer therapeutics market is expected to grow significantly in the future. North America dominated the global lung cancer therapeutics market over the past few years. The high demand in the region was sustained by factors which include increasing occurrences of lung cancer and rising levels of geriatric population. Asia-Pacific is projected to foresee the highest growth rate in the global lung cancer therapeutics market over the next eight years. Lung cancer is the leading cause of death in Europe, accounting for approximately 350 million deaths annually.
Increasing prevalence of respiratory diseases owing to the growing aging population and increasing pathogens in the environment has been the key factor driving the asthma and chronic obstructive pulmonary disease (COPD) market globally. Worldwide US continent is the largest market for COPD. A recent market assessment study shows that COPD is the major cause of death, whose prevalence is on the rise and is predicted to be the third leading cause of death globally by 2030. Increase in commonness of COPD, increment in the geriatric populace and development of the pharmaceutical business are foreseen to fuel the development of COPD treatment market in Asia Pacific.
Major Medicine Universities:
University of Minnesota
Pittsburgh School of Medicine
Mayo Medical School
John Hopkins University
The University of Oxford Stanford University
University of Cambridge
In Asia Pacific:
The Chinese University of Hon Kong (CUHK)
Seoul National University
National Taiwan University
National University of Singapore (NUS)
University of Hong Kong (HKU)
Societies related to Cancer:
Translational research in Oncology
Institut Curie-Pole Developmental Biology
Saint- Louis Hospital
Bichat- Claude Bernard Hospital
Texas Oncology- Paris
Gustave Roussy Institute of Oncology
Hospital Group Paris Saint- Joseph
In Asia Pacific:
Childhood Cancer International Netherlands
The Asia Pacific Prostate Society
The Max Foundation
The Asia Pacific Cancer Society Training
Irish Cancer Society
Cancer Research UK
Peter McCollum Cancer Centre
American Society of Clinical Oncology (ASCO)
International Agency for Research on Cancer (IACR)
American Association for Cancer Research
International Cancer Research Partnership (ICRP)
National Cancer Institute (NIC)
The European Cancer Organization (ECCO)
Hospitals Associated with Cancer:
Medical Excellence JAPAN
Japan Community Healthcare Organization Chukyo Hospital
Aichi Cancer Center Hospital
Kyoto University Hospital
Japanese Red Cross Nagoya Daiichi Hospital
Dokkyo Medical University Hospital
Japan Hospital Association
University Hospital Kumamoto University
International Medical Center of Japan
Leiden University Medical Center
Royal Cancer Hospital
King’s College Hospital
Clattlerbridge Center for Oncology
Northampton General Hospital
Cambridge University Hospitals
University of Hospital Southhampton
Central Manchester University Hospitals
Southend University Hospital
New York Presbyterain Hospital
Memorial Sloan Kettering Cancer Center
Mayo Clinic Rochester
MD Anderson Cancer Center, Texas
John Hopkins Hospital, Baltimore
University of Washington Medical Center
Massachusetts General Hospital
UCSF Medical Center
UCLA Medical Center